About Ubiquitin carboxyl-terminal hydrolase 48
Ubiquitin carboxyl-terminal hydrolase 48 (USP48) is a protein
from Homo sapiens identified by UniProt accession
Q86UV5, 1035 residues long.
MolForge cross-references it against 0 known binders and
63 disease associations.
Target properties
| Protein name | Ubiquitin carboxyl-terminal hydrolase 48 |
|---|
| UniProt accession | Q86UV5 |
|---|
| Gene | USP48 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1035 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (63)
Diseases linked to this target (Open Targets).
- nonsyndromic genetic hearing loss · score 0.37
- autosomal dominant nonsyndromic hearing loss · score 0.37
- type 2 diabetes mellitus · score 0.27
- ovarian cancer · score 0.23
- breast adenocarcinoma · score 0.23
- Immature Reticulocyte Fraction Measurement · score 0.21
- testosterone measurement · score 0.19
- reticulocyte count · score 0.18
- mean reticulocyte volume · score 0.17
- reticulocyte measurement · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86UV5-F1 | alphafold | PREDICTED | 81.07 | — |
Amino-acid sequence (1035 residues)
MAPRLQLEKA AWRWAETVRP EEVSQEHIET AYRIWLEPCI RGVCRRNCKG NPNCLVGIGE HIWLGEIDEN SFHNIDDPNC ERRKKNSFVG LTNLGATCYV NTFLQVWFLN LELRQALYLC PSTCSDYMLG DGIQEEKDYE PQTICEHLQY LFALLQNSNR RYIDPSGFVK ALGLDTGQQQ DAQEFSKLFM SLLEDTLSKQ KNPDVRNIVQ QQFCGEYAYV TVCNQCGRES KLLSKFYELE LNIQGHKQLT DCISEFLKEE KLEGDNRYFC ENCQSKQNAT RKIRLLSLPC TLNLQLMRFV FDRQTGHKKK LNTYIGFSEI LDMEPYVEHK GGSYVYELSA VLIHRGVSAY SGHYIAHVKD PQSGEWYKFN DEDIEKMEGK KLQLGIEEDL AEPSKSQTRK PKCGKGTHCS RNAYMLVYRL QTQEKPNTTV QVPAFLQELV DRDNSKFEEW CIEMAEMRKQ SVDKGKAKHE EVKELYQRLP AGAEPYEFVS LEWLQKWLDE STPTKPIDNH ACLCSHDKLH PDKISIMKRI SEYAADIFYS RYGGGPRLTV KALCKECVVE RCRILRLKNQ LNEDYKTVNN LLKAAVKGSD GFWVGKSSLR SWRQLALEQL DEQDGDAEQS NGKMNGSTLN KDESKEERKE EEELNFNEDI LCPHGELCIS ENERRLVSKE AWSKLQQYFP KAPEFPSYKE CCSQCKILER EGEENEALHK MIANEQKTSL PNLFQDKNRP CLSNWPEDTD VLYIVSQFFV EEWRKFVRKP TRCSPVSSVG NSALLCPHGG LMFTFASMTK EDSKLIALIW PSEWQMIQKL FVVDHVIKIT RIEVGDVNPS ETQYISEPKL CPECREGLLC QQQRDLREYT QATIYVHKVV DNKKVMKDSA PELNVSSSET EEDKEEAKPD GEKDPDFNQS NGGTKRQKIS HQNYIAYQKQ VIRRSMRHRK VRGEKALLVS ANQTLKELKI QIMHAFSVAP FDQNLSIDGK ILSDDCATLG TLGVIPESVI LLKADEPIAD YAAMDDVMQV CMPEEGFKGT GLLGH
Explore Ubiquitin carboxyl-terminal hydrolase 48 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets